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Jesper Eugen-Olsen4 and Line J. H. Rasmussen4
Abstract
Background: The inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is elevated in
severe acute and chronic medical conditions and has been associated with short-term mortality. The role of suPAR
in predicting risk of death following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) has
never been studied. We hypothesized that increased suPAR is an independent predictor of short-term mortality in
patients admitted to hospital with COPD or acute respiratory failure.
Methods: This retrospective cohort study from a university hospital in the Capital Region of Denmark included
2838 acutely admitted medical patients with COPD as primary (AECOPD) or secondary diagnosis, who had plasma
suPAR measured at the time of admission between November 18th, 2013 to September 30th, 2015 and followed
until December 31st, 2015. Primary outcomes were 30- and 90-days all-cause mortality. Association of suPAR
and mortality was investigated by Cox regression analyses adjusted for age, sex, CRP values and Charlson
comorbidity index.
Results: For patients with AECOPD or underlying COPD, median suPAR levels were significantly higher among
patients who died within 30 days compared with those who survived (5.7 ng/ml (IQR 3.8–8.1) vs. 3.6 ng/ml
(2.7–5.1), P < 0.0001). Increasing suPAR levels independently predicted 30-day mortality in patients with COPD
with a hazard ratio of 2.0 (95% CI 1.7–2.4) but not respiratory failure.
Conclusions: In this large group of acutely admitted patients with COPD, elevated suPAR levels were associated with
increased risk of mortality. The study supports the value of suPAR as a marker of poor prognosis.
Keywords: COPD exacerbation, Mortality, Biomarker, Hospitalisation
Background
Chronic obstructive pulmonary disease (COPD) is world-
wide a leading cause of morbidity and mortality, posing a
considerable socioeconomic burden to society [1]. COPD is
a highly complex disease with symptoms not only related
to the respiratory system. In many patients with COPD, the
course of the disease will be progressive with a gradual
decline in health status and increasing frequency and sever-
ity of acute exacerbations (AECOPD). This progressive
course of the disease is associated with a substantial in-
crease in all-cause mortality. In the clinical assessment of
the severity of the disease, the GOLD classification is often
applied [1]. However, improved risk prediction in patients
with COPD would be of great value, in particular if it
additionally would facilitate identification of terminal ill
patients in need of enhanced preventive efforts, palliative
care or other interventions.
Several biomarkers have, in studies of stable COPD,
been associated with disease severity and mortality risk
[2]. A history of frequent exacerbations of COPD is per
se a marker of poor prognosis [3]. However, diagnostic
and/or prognostic markers in unstable disease have so
far provided variable results. In the ECLIPSE cohort,
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previous exacerbations, older age, high white blood cell
count, emphysema, severe airflow limitation and poor
health status were associated with increased risk of future
hospitalizations [4]. A meta-analysis of routine blood-tests
in AECOPD found that anaemia, hypoalbuminemia and
elevated levels of the cardiac biomarkers pro-BNP and
troponin-T, but not high-sensitivity C-reactive protein (hs-
CRP) predicted mortality from COPD [5]. By contrast, a
recent systematic review found CRP to be the only robust
biomarker showing consistently elevated levels in AECOPD
compared with control groups [6]. Recently, a readmission
and mortality risk prediction score, comprising previous
admissions, extended dyspnoea grade, age and heart failure
but no biomarkers, has been proposed [7].
Previous studies have shown that the urokinase plas-
minogen activator receptor (uPAR) is involved in the
pathogenesis (both small airway fibrosis and emphy-
sema) of COPD through complex molecular pathways
and gene expression patterns [8–10]. Soluble urokinase
plasminogen activator receptor (suPAR) is the soluble
form of the uPAR receptor and can be measured in
blood/plasma. suPAR is considered an inflammatory bio-
markerand is elevated in both acute and chronic illness.
It is a non-specific risk marker with a diagnostic cut-off
value of approximately 3 ng/ml [11]. However, little is
known about suPAR in relation to disease status and
mortality in COPD. suPAR has previously in a small
study been found to be superior to CRP and fibrinogen
in the prediction of AECOPD and in monitoring treat-
ment of exacerbation [12]. Furthermore, suPAR levels
are increased in stable COPD compared to healthy con-
trols [13]. Finally, suPAR has been shown to predict a
range of chronic conditions and mortality in the general
population as well as being associated with risk of
readmission and mortality in a large group of acutely
admitted medical patients, with AECOPD constituting a
subgroup of these [14, 15].
In this study, we aimed to investigate the value of
suPAR levels in plasma upon hospital admission as a
prognostic biomarker for short-term mortality in COPD
patients based on a large, unselected population of
acutely admitted medical patients.
Methods
Study design and population
This retrospective, registry-based cohort study was carried
out in the Acute Medical Unit (AMU), Copenhagen Uni-
versity Hospital Hvidovre, Denmark, and included acute
medical patients admitted from November 18th, 2013,
until September 30th, 2015. The patients were followed in
national registries for up to 90 days. The AMU receives
unselected, adult internal medical patients within all spe-
cialties, except medical gastroenterology and patients re-
quiring isolation due to infections or suspected acute
myocardial infarction in need of PCI. Upon
hospitalization, all patients routinely have a set of standard
blood tests analysed, including blood cell count, electro-
lytes, analyses of kidney- and liver function, and CRP.
Since November 18, 2013, suPAR has been included in
this biomarker panel as a routine analysis. All patients,
who were admitted to the AMU throughout the described
period and had suPAR measured as part of the admission
blood samples, were included in the present study.
For each patient, an index admission was defined as
the first admission in which the patient had suPAR
measured. Data on plasma suPAR levels and other blood
tests were obtained from the electronic hospital database
LABKA via the Department of Clinical Biochemistry.
Hospital admission and discharge as well as information
on diagnoses were obtained from the Danish National
Patient Registry (NPR), [16] and for this study we
included patients with the International Classification of
Diseases, 10th edition (ICD-10) diagnoses for COPD
(J440, J441, J449) or respiratory failure (J96X) at the
index admission. Data on vital status was obtained from
the Civil Registration System, in which all Danish citi-
zens are registered with a unique personal identifica-
tion number [17]. Follow-up was 30 or 90 days. For
this study, three COPD populations of interest were
defined based on the patients’ diagnoses at the time
of the index admission:
1. Patients admitted with acute exacerbation of COPD
as the primary diagnosis during the index admission
(AECOPD)
2. Patients admitted with a diagnosis of COPD
registered as the primary diagnosis before or during
the index admission (any COPD)
3. Patients admitted with respiratory failure as the
primary diagnosis during the index admission and
with a registration of COPD as secondary or any
other order of diagnosis during the index admission
(Respiratory failure)
Thus, patients belonging to the groups AECOPD and
Respiratory failure are also included in any COPD. How-
ever, no patient appeared more than once in the analyses,
i.e. readmissions were not included in the study.
Outcomes and covariates
The primary outcomes were death from any cause within
30 or 90 days after admission, respectively. Secondary out-
come was analysis of the interaction between levels of
suPAR and CRP.
Covariates included in the adjusted analyses were age,
sex, Charlson comorbidity index (Charlson score), and
CRP.
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The Charlson score was calculated for each patient as
a measure of the patients’ comorbid conditions using a
SAS macro, [18] and using the updated weights defined
by Quan et al. [19] Assessment of the Charlson score
was calculated from diagnoses registered in the NPR up
to 2 years prior to the index admission.
Measurements
Plasma suPAR levels were measured using the suPAR-
nostic AUTO Flex ELISA kit (ViroGates A/S, Birkerød,
Denmark) as described in detail previously [15]. The
suPARnostic® ELISA measures the full length suPAR
molecule (D1D2D3) as well as the cleaved suPAR mol-
ecule (D2D3).CRP was measured using a COBAS 6000
analyser (Roche Diagnostics, Mannheim, Germany).
Statistical analysis
Continuous variables are presented as median and inter-
quartile range (IQR) and categorical variables are pre-
sented as numbers (n) and percentages (%).
We used both univariate and adjusted Cox regression
analyses to estimate the effect of suPAR on time to death.
Results are presented as hazard ratios (HRs) with 95%
confidence intervals (CIs). The adjusted analyses were
controlled for age, sex, Charlson score, and CRP. For the
Cox regression analyses, suPAR was log2-transformed or
stratified in quartiles.
Survival for suPAR- or CRP quartiles is presented in
Kaplan-Meier plots for each of the three COPD groups.
Finally, we performed ROC curve analyses for 90-days
mortality in the three groups using DeLongs test for two
correlated ROC curves (with and without suPAR).
SAS Enterprise Guide 7.11 (SAS Institute) and R 3.2.3
(The R Foundation for Statistical Computing) were used
for statistical analysis. R 3.2.3 was used to create the figures.
A P < 0.05 was considered to be statistically significant.
Results
SuPAR was measured in > 95% of all acutely admitted
patients. During the inclusion period, a total of 717,
2573 and 265 patients with AECOPD, any COPD and
Respiratory failure due to COPD, respectively, were
admitted to the AMU and had suPAR measured. The
median age was 72.8, 73.4 and 73.4 years, respectively,
and median length of stay was 3.2, 2.2 and 5.9 days,
respectively. In all three groups there were slightly more
women than men who were admitted with COPD or
respiratory failure (Table 1). In the group with AECOPD,
6.4% died within 30 days from the index admission, and
13.4% died within 90 days. For patients with any COPD
or Respiratory failure the numbers were 9.1, 14.4 and
20.8% and 26.8%, respectively.
High suPAR and CRP are associated with increased risk of
mortality
In all groups, except for patients admitted with Respiratory
failure by 30 days of follow-up, median suPAR levels were
significantly higher among those who died within 30 or
90 days of follow-up compared with patients who survived
(Table 2). When stratifying the groups by suPAR quartiles,
there was a significant relationship between increasing
suPAR level and mortality by 30 or 90 days except in
patients with Respiratory failure (Table 2, Fig. 1). Repeating
the analyses by quartiles of CRP showed that increasing
CRP was associated with both 30 and 90-day mortality in
AECOPD only and with 90 days mortality in any COPD
(Table 2, Fig. 2). For patients with acute respiratory failure
and COPD there was, however, a trend towards increased
90-day mortality in the highest suPAR quartile/interval.
suPAR levels independently predict mortality risk
The survival analyses showed that suPAR is an inde-
pendent predictor of 30- and 90-day mortality in pa-
tients admitted withAECOPD or any other medical
condition with underlying COPD. In the multivariable
models adjusted for age, sex, Charlson score and CRP, a
doubling of the suPAR values (log2-transformed), gave
HRs of 1.83 (95% CI: 1.21–2.79, p = 0.005), 2.17 (95%
CI: 1.62–2.89, p < 0.0001) and 2.02 (95% CI: 1.69–2.41,
p < 0.0001), 1.91 (95% CI: 1.66–2.20, p < 0.0001) for
death by 30- and 90 days in the two groups, respectively
(Table 3). Similarly, in the fully adjusted models by quar-
tiles of suPAR, the HRs were higher in the highest
suPAR quartiles compared with the lowest (Table 3).
Age, sex and Charlson score were also independent risk
factors for mortality in all three groups, whereas CRP
only predicted subsequent mortality in the largest popu-
lation (any COPD). When CRP was entered as a linear
variable in the analyses, p < 0.0001 for 30- and 90-day
mortality, and when CRP was divided by quartiles HRs
Table 1 Patient demographics and covariates at the index
admission in patients with COPD as primary diagnosis, underlying
COPD and respiratory failure due to COPD
AECOPD any COPD Respiratory
failure
N (%) 717 (20.2) 2573 (72.4) 265 (7.4)
Men 311 (43.4) 1142 (44.4) 109 (41.1)
Women 406 (56.6) 1431 (55.6) 156 (58.9)
Age (years) 72.8 (64.0–79.9) 73.4 (63.6–81.3) 73.4 (65.9–78.0)
Charlson score 1.0 (0–11) 1.0 (0–11) 1.0 (0–11)
Length of stay
(days)
3.2 (0.8–7.8) 2.2 (0.7–6.8) 5.9 (1.8–12.0)
CRP (mg/L) 24.0 (6.0–75.0) 15.0 (4.0–65.0) 26.0 (7.0–86.0)
suPAR (ng/mL) 3.5 (2.6–5.0) 3.8 (2.8–5.4) 3.8 (2.8–5.3)
Values are presented as percentages or median (IQR)
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Table 2 Mortality rates in patients with AECOPD, any COPD, or Respiratory failure due to COPD, respectively, stratified according to
suPAR and CRP quartilesa
AECOPD any COPD Respiratory failure
Survived Died p-value Survived Died p-value Survived Died p-value
30-day mortality 671 (93.6%) 46 (6.4%) 2338 (90.1%) 235 (9.1%) 210 (79.3%) 55 (20.7%)
suPAR (ng/ml),
median (IQR)
3.5 (2.6–4.9) 4.5 (3.5–5.8) 0.0004 3.6 (2.7–5.1) 5.7 (3.8–8.1) < 0.0001 3.8 (2.8–5.1) 4.1 (3.0–6.3) 0.14
CRP (mg/L),
median (IQR)
21 (5–75) 46 (15–86) 0.03 13 (4–57) 71 (20–160) < 0.0001 21.5 (6–80) 43 (8.5–115) 0.14
suPAR quartile 1 176 (97.2%) 5 (2.8%) 594 (97.2%) 17 (2.8%) 58 (82.9%) 12 (17.1%)
suPAR quartile 2 176 (95.6%) 8 (4.4%) 634 (94.6%) 36 (5.4%) 51 (79.7%) 13 (20.3%)
suPAR quartile 3 165 (91.2%) 16 (8.8%) 583 (91.2%) 56 (8.8%) 54 (81.8%) 12 (18.2%)
suPAR quartile 4 154 (90.1%) 17 (9.9%) 0.01b 527 (80.7%) 126 (19.3%) < 0.0001b 47 (72.3%) 18 (27.7%) 0.44b
CRP quartile 1 186 (96.9%) 6 (3.1%) 622 (96.4%) 23 (3.6%) 57 (80.3%) 14 (19.7%)
CRP quartile 2 166 (94.3%) 10 (5.7%) 619 (95.5%) 29 (4.5%) 54 (85.7%) 9 (14.3%)
CRP quartile 3 154 (90.1%) 17 (9.9%) 577 (89.6%) 67 (10.4%) 51 (77.3%) 15 (22.7%)
CRP quartile 4 165 (92.7%) 13 (7.3%) 0.06b 520 (81.8%) 116 (18.2%) < 0.0001b 48 (73.8%) 17 (26.2%) 0.40b
90-day mortality 621 (86.6%) 96 (13.4%) 2203 (85.6) 370 (14.4%) 194 (73.2%) 71 (26.8%)
suPAR (ng/ml),
median (IQR)
3.3 (2.6–4.6) 4.7 (3.7–6.2) < 0.0001 3.6 (2.7–5.0) 5.4 (3.8–7.5) < 0.0001 3.7 (2.8–5.0) 4.2 (3.0–6.3) 0.03
CRP (mg/L),
median (IQR)
20 (5–75.5) 41 (13–73) 0.005 12 (3–54) 61 (16–130) < 0.0001 19 (6–82) 43 (7–110) 0.11
suPAR quartile 1 174 (96.1%) 7 (3.9%) 583 (95.4%) 28 (4.6%) 55 (78.6%) 15 (21.4%)
suPAR quartile 2 169 (91.9%) 15 (8.1%) 614 (91.6%) 56 (8.4%) 49 (76.6%) 15 (23.4%)
suPAR quartile 3 149 (82.3%) 32 (17.7%) 540 (84.5%) 99 (15.5%) 49 (74.2%) 17 (25.8%)
suPAR quartile 4 129 (75.4%) 42 (24.6%) < 0.0001b 466 (71.4%) 187 (28.6%) < 0.0001b 41 (63.1%) 24 (36.9%) 0.18b
CRP quartile 1 178 (92.7%) 14 (7.3%) 605 (93.8%) 40 (6.2%) 52 (73.2%) 19 (26.8%)
CRP quartile 2 155 (88.1%) 21 (11.9%) 593 (91.5%) 55 (8.5%) 51 (81.0%) 12 (19.0%)
CRP quartile 3 133 (77.8%) 38 (22.2%) 537 (83.4%) 107 (16.6%) 46 (69.7%) 20 (30.3%)
CRP quartile 4 155 (87.1%) 23 (12.9%) 0.0004b 468 (73.6%) 168 (26.4%) < 0.0001b 45 (69.2%) 20 (30.8%) 0.41b
aThe cut-offs for the suPAR quartiles in each population were as follows: AECOPD: Q1: ≤2.6 ng/ml, Q2: 2.7–3.5 ng/ml, Q3: 3.6–5.0 ng/ml, Q4: > 5 ng/ml. Any COPD:
Q1: ≤2.7 ng/ml, Q2: 2.8–3.7 ng/ml, Q3: 3.8–5.3 ng/ml, Q4: ≥5.4 ng/ml. Respiratory failure: Q1: ≤2.8 ng/ml, Q2: 2.9–3.8 ng/ml, Q3: 3.9–5.3 ng/ml, Q4: ≥5.4 ng/ml
The cut-offs for the CRP quartiles in each population were as follows: AECOPD: Q1: < 6 mg/l, Q2: 6–23 mg/l, Q3: 24–74 mg/l, Q4:≥75 mg/l. Any COPD: Q1: < 4 mg/l,
Q2: 4–14 mg/l, Q3: 15–64 mg/l, Q4: ≥65 mg/l. Respiratory failure: Q1: < 7 mg/l, Q2: 7–25 mg/l, Q3: 26–85 mg/l, Q4: ≥86 mg/l.
bChi2-tests by increasing suPAR and CRP-quartiles
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Fig. 1 Kaplan-Meier plots of 90-day survival by suPAR quartiles. a Primary COPD, b Prevalent COPD, c Respiratory failure
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in the highest quartiles compared to the lowest were
3.27 (95% CI: 2.06–5.20, p < 0.0001) and 2.90 (95%
CI: 2.03–4.15, p < 0.0001) for 30- and 90-day mortal-
ity, respectively.
The ROC curve analyses confirmed that there were
significant differences for the AUC, when suPAR was
added to age, sex, Charlson score and CRP in the two
COPD groups but not for Respiratory failure (not
shown).Calculations of the sensitivity and specificity of
log-transformed suPAR yielded values of 0.78 and 0.49,
respectively, for 30- days mortality in the largest patient
group (Additional file 1: Table S1).
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Fig. 2 Kaplan-Meier plots of 90-day survival by CRP quartiles. a Primary COPD, b Prevalent COPD, c Respiratory failure
Table 3 Thirty- and 90-day mortality risk, expressed as hazard ratios, by suPAR levels, entered as either continuous (log-transformed)
or in quartiles, at index admission in patients with AE COPD, any COPD and Respiratory failure due to COPD
Outcome Analysis Variable AECOPD (n = 717) any COPD (n = 2573) Respiratory failure (n = 265)
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
30-day mortalityb Univariate Continuous 2.2 (1.5–3.2) < 0.0001 2.5 (2.1–2.9) < 0.0001 1.5 (1.0–2.1) 0.04
1.quartile 1 1 1
2.quartile 1.6 (0.5–4.9) 0.42 2.0 (1.1–3.5) 0.02 1.2 (0.6–2.7) 0.62
3.quartile 3.3 (1.2–9.0) 0.02 3.3 (1.9–5.6) < 0.0001 1.1 (0.5–2.4) 0.82
4.quartile 3.7 (1.4–10.1) 0.01 7.6 (4.6–12-6) < 0.0001 1.8 (0.9–3.7) 0.12
Multivariatea Continuous 1.8 (1.2–2.8) 0.005 2.0 (1.7–2.4) < 0.0001 1.3 (0.8–2.0) 0.23
1.quartile 1 1 1
2.quartile 1.2 (0.4–3.8) 0.73 1.5 (0.8–2.6) 0.20 1.2 (0.5–2.7) 0.66
3.quartile 2.3 (0.8–6.6) 0.11 1.8 (1.1–3.2) 0.03 0.8 (0.4–1.9) 0.65
4.quartile 2.0 (0.7–5.7) 0.20 3.4 (2.0–5.9) < 0.0001 1.3 (0.6–2.8) 0.50
90-day mortalityc Univariate Continuous 2.5 (2.0–3.3) < 0.0001 2.3 (2.1–2.6) < 0.0001 1.5 (1.1–2.2) 0.01
1.quartile 1 1 1
2.quartile 2.1 (0.9–5.3) 0.1 1.9 (1.2–2.9) 0.007 1.1 (0.6–2.4) 0.72
3.quartile 4.9 (2.2–11-1) 0.0001 3.6 (2.4–5.4) < 0.0001 1.0 (0.5–2.1) 0.98
4.quartile 7.1 (3.2–15.8) < 0.0001 7.3 (4.9–10.8) < 0.0001 1.6 (0.8–3.1) 0.20
Multivariatea Continuous 2.2 (1.6–2.9) < 0.0001 2.3 (2.1–2.6) < 0.0001 1.4 (1.0–2.1) 0.06
1.quartile 1 1 1
2.quartile 1.8 (0.7–4.5) 0.19 1.5 (0.8–2.6) 0.20 1.1 (0.6–2.4) 0.72
3.quartile 3.9 (1.7–8.9) 0.001 1.8 (1.1–3.2) 0.03 1.0 (0.5–2.1) 0.98
4.quartile 4.3 (1.9–9.9) 0.0005 3.4 (2.0–5.9) < 0.0001 1.6 (0.8–3.1) 0.20
aAdjusted for age, sex, Charlson score and CRP
bNumber of events were 45, 227 and 52 in AECOPD, any COPD and Respiratory failure, respectively
cNumber of events were 93, 358 and 67 in AECOPD, any COPD and Respiratory failure, respectively
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Interaction between CRP and suPAR
To assess whether the association between suPAR levels
and mortality was mediated through a concomitant in-
crease in CRP, we performed interaction analyses with
CRP as a linear, continuous variable and suPAR as either
a continuous variable or log-transformed in separate
analyses for all three groups and for both 30- and 90-day
mortality. There was no significant interaction between
the two biomarkers except for 90-day mortality in the
largest group when entering suPAR as a continuous vari-
able (p = 0.04) (data not shown).
Discussion
This retrospective cohort study in a population of patients
admitted to a University hospital with AECOPD or any
acute medical condition with underlying COPD showed
that the inflammatory biomarker suPAR was independ-
ently associated with all-cause mortality. Furthermore, we
showed that median suPAR levels were higher among
those who died within 90 days of admission compared
with those who survived in all three groups of respiratory
patients. Interaction analyses showed that these effects
were not mediated through concomitantly elevated CRP,
although this biomarker was also independently associated
with mortality, but less consistently compared to suPAR.
This is consistent with previous findings and the value of
CRP in combination with other biomarkers as indicators
of poor prognosis in COPD has also recently been
confirmed in a study comprising patients from the COPD-
Gene- and the ECLIPSE cohorts [6, 20].
To our knowledge, this is the first large-scale study
investigating the relationship between this recently in-
troduced prognostic biomarker and COPD. The mortal-
ity rate in the present study did not differ from other
studies of mortality in relation to severe AECOPD [21].
The magnitude of the association corresponds well with
other studies that specifically have addressed the role of
suPAR as prognostic indicator of mortality in acutely ill
patients [15, 22, 23]. However, the vast majority of previ-
ous studies have investigated suPAR in cohorts of
patients with systemic inflammatory response syndrome
(SIRS) or sepsis in an intensive care unit setting, which
makes comparisons of the present study with previous
findings challenging. The sensitivity and specificity of
suPAR regarding mortality in the present study is
comparable with pooled values from a recent systematic
review of suPAR and bacterial infections [24]. A very
recent study of chronic heart failure (CHF), a condition
which has the chronic, systemic inflammation in com-
mon with COPD, found that elevated suPAR levels ap-
proximately doubled the risk of subsequent mortality
during 3 years of follow-up [25]. This was, however,
stable patients in an outpatient setting. A Danish study
of 449 patients consecutively admitted to hospital with
chest pain and followed for up to 6.6 years found that
suPAR was associated with increased all-cause mortality
independent of other variables reflecting myocardial
ischaemia (HR 1.93) [26]. Only one small cross-sectional
study comprising 43 patients has measured suPAR upon
hospitalisation with AECOPD and found it to be higher
than in healthy controls [12] and also that suPAR corre-
lated negatively with level of FEV1. Furthermore, suPAR
levels decreased after 7 days, but whether this was a
treatment effect or occurred spontaneously remains un-
known. Two other small studies of stable COPD patients
matched with healthy control subjects found opposite
effects regarding suPAR levels [13, 27]. Thus, the value
of adding suPAR to routine blood samples in hospita-
lised AECOPD for subsequent risk prediction has so far
been largely unexplored. It has previously been demon-
strated that the cell-bound form of suPAR (uPAR) is
highly expressed in the small airway epithelia of patients
with COPD compared with normal controls and that
increased uPAR expression in the small airway epithe-
lium of patients with COPD participates in an active
epithelial-mesenchymal transition process [8, 9]. Assum-
ing that increased uPAR expression results in increased
uPAR cleavage and suPAR generation, the observations
by Wang and co-workers are supported by our observa-
tion of increased suPAR and worse prognosis in COPD.
Given the pathophysiological mechanisms of most
cases of AECOPD, namely a flare-up in acute local and
systemic inflammatory mediators and airway bacterial or
viral infection, [28] a high level of an unspecific inflam-
matory biomarker such as suPAR is expected. As suPAR
is a very stable biomarker, it may be less affected by the
exacerbation and more reflective of the underlying
chronic condition, which may explain its high prognostic
power in AECOPD.
In AECOPD no single biomarker or clinical test, apart
from sustained respiratory acidosis measured in an arterial
puncture, can accurately predict the immediate or short-
term (less than 3 months) outcome [29]. Previous studies
have proposed either a panel of biomarkers, a composite
measure of clinical features and blood tests e.g. as a “pre-
diction score tool” or simply an assessment of demo-
graphic variables for determining the risk for hospital
readmission or death from COPD [2–7]. In terms of novel
biomarkers of prognosis in COPD, the study by Stolz et al.
[2] found that simultaneously elevated plasma levels of
the three biomarkers adrenomedullin, arginine vasopres-
sin and atrial natriuretic peptide were associated with
increased mortality risk during a 5-year follow-up in
patients with stable COPD. An assessment of adrenome-
dullin alone or in combination with composite measures
such as age, grade of dyspnea and degree of airflow ob-
struction conveyed an increased mortality risk comparable
to the observations in the present study [30]. However,
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the patients in this study were derived from several
cohorts of patients who also had stable disease. Further-
more, a number of the scoring tools that have been devel-
oped for predicting future risk of readmission or death
from AECOPD are quite complex or include measures of
cardiovascular comorbidity, which may not be readily
accessible in the acute setting [7, 31]. None of the scoring
systems seem to agree upon, which few key parameters
are considered superior in the prediction of severe and/or
fatal incidents of AECOPD. The latest publication pro-
poses an 8-item scoring tool for predicting 1-year mortal-
ity after a first hospitalization for AECOPD [32]. The
variables associated with increased risk included older age,
male sex, having a severe exacerbation, longer duration of
the disease and hospital stay, prior hospital admissions, a
diagnosis of cancer and a higher Charlson score. A num-
ber of these were already predefined as important con-
founders and included as covariates in the present study
[15]. Interestingly, a study aimed at predicting 12-month
mortality in elderly patients presenting to the emergency
ward, by asking the attending physicians the so-called
“surprise question” (“Would you be surprised whether this
patient died in the next 12 months?”) suggested a fair
sensitivity but poor specificity [33]. When combined
with other determinants of unfavourable outcome, al-
though not including any blood-based biomarkers, re-
sults remained unchanged.
For admission with respiratory failure and COPD as
secondary diagnosis we found no statistical significant
relationship between suPAR and mortality, although
there was a tendency when entering suPAR as a continu-
ous variable for death by 90 days (p = 0.06, Table 3). This
may in part be due to the small numbers, especially
when analysis is performed by suPAR quartiles. Never-
theless, this finding is somewhat unexpected and needs
further investigation. Patients with acute, hypercapnic
respiratory failure have an even higher risk of in-hospital
or short-term mortality than patients belonging to either
of the other groups, [29] which is why a stronger rela-
tionship would be anticipated in this group. The 30- and
90 days mortality rates were approximately doubled in
the Respiratory failure group compared with the other
groups, indicating that the negative results from the
survival analyses represent a statistical lack of power
rather than a true association.
Limitations of the present study include lack of data
on smoking status as suPAR is confounded by smoking
[34]. The Danish patient registries are validated and
diagnoses are registered upon hospital discharge or in-
hospital death but some inaccuracy may occur, although
misclassification of the diagnoses in question is normally
not a major source of bias [35]. Furthermore, this study
did not discriminate the patients by other indicators of
increased mortality risk such as number of previous
exacerbations, need for non-invasive ventilation or refer-
ral to intensive care unit, level of FEV1, dyspnoea grade,
BMI or socioeconomic status. However, regarding FEV1,
the new GOLD guidelines recognize that a hospitalisa-
tion for COPD is more predictive of worsened prognosis
than lung function [1]. Nevertheless we cannot rule out
that patients with high levels of suPAR also had lower
FEV1. Also, measurement of blood-eosinophils was only
available in a minority of the patients. Another limita-
tion is that suPAR values were only measured at hospital
admission, and thus it was not possible to assess
whether this biomarker changed according to therapy or
disease course in general. In future studies of AECOPD
it would also be useful to analyse how suPAR can con-
tribute to already existing prediction scores for readmis-
sion and/or death.
Conclusions
We have shown that suPAR levels are elevated in pa-
tients admitted to a large university hospital with COPD
as primary or secondary diagnosis, who died within 30-
or 90 days of follow-up compared with patients, who
survived. The risk of death within 30- or 90 days after
admission was doubled with increasing levels of suPAR
for patients with AECOPD or any medical condition and
underlying COPD, which is consistent with other stud-
ies. suPAR seems to be independent of- and better than
CRP in discriminating an adverse outcome. It is there-
fore suggested that measurement of suPAR can be used
as an indicator of poor prognosis in patients with more
severe acute exacerbation of COPD.
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